References
- European Centre for Disease Prevention and Control. 2021. [accessed 20 Feb 2021]. Available from: https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea
- Polack FP, Thomas SJ, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
- Baden LR, El Sahly HM, Essink B, et al.; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020. Epub ahead of print. DOI:10.1056/NEJMoa2035389
- Center for Disease Control and Prevention. 2021. [accessed 20 Feb 2021]. Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
- Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021. DOI:10.1056/NEJMoa2034201
- Callaway E. The coronavirus is mutating - does it matter? Nature. 2020;585:174–177.
- Center for Disease Control and Prevention. 2021. [accessed 15 Feb 2021]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html